Lv1
38 积分 2023-11-19 加入
EP08.02-158 Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-negative NSCLC
5天前
已完结
1036P Anlotinib plus docetaxel vs. docetaxel as 2nd-line treatment of advanced non-small cell lung cancer (NSCLC): Updated results from ALTER-L016
5天前
已关闭
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer
9天前
已完结
The interplay between gut microbiota, antibiotics, and immune checkpoint inhibitors in patients with cancer: A narrative review with biological and clinical aspects
10天前
已完结
Therapeutic Targeting of Tumor-Infiltrating Regulatory T Cells in Breast Cancer
12天前
已完结
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer
12天前
已完结
Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma
15天前
已完结
Unraveling Resistance in Lung Cancer Immunotherapy: Clinical Milestones, Mechanistic Insights, and Future Strategies
15天前
已完结
Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs
1个月前
已完结
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back
1个月前
已完结
皖公网安备34019202002308
